Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells

[1]  M. Reginato,et al.  Progress toward overcoming hypoxia-induced resistance to solid tumor therapy , 2015, Cancer management and research.

[2]  Capucine Van Rechem,et al.  Hypoxia drives transient site-specific copy gain and drug-resistant gene expression , 2015, Genes & development.

[3]  Ning Wang,et al.  Cancer survival in China, 2003–2005: A population‐based study , 2015, International journal of cancer.

[4]  J. Patki,et al.  HSP90: Chaperone-me-not , 2013, Pathology & Oncology Research.

[5]  H. Gali-Muhtasib,et al.  Targeting hypoxia for sensitization of tumors to radio- and chemotherapy. , 2013, Current cancer drug targets.

[6]  T. Haystead,et al.  Hsp90, an unlikely ally in the war on cancer , 2013, The FEBS journal.

[7]  J. Petersen,et al.  Imaging hypoxia to improve radiotherapy outcome , 2012, Nature Reviews Clinical Oncology.

[8]  P. Schemmer,et al.  Treatment of Hepatocellular Carcinoma: A Systematic Review , 2012, Liver Cancer.

[9]  M. Lotze,et al.  High‐mobility group box 1 activates caspase‐1 and promotes hepatocellular carcinoma invasiveness and metastases , 2012, Hepatology.

[10]  N. Curtin,et al.  Targeting the S and G2 checkpoint to treat cancer. , 2012, Drug discovery today.

[11]  T. Wang,et al.  Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[13]  P. Workman,et al.  A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors , 2011, Clinical Cancer Research.

[14]  Junji Furuse,et al.  The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. , 2010, The oncologist.

[15]  E. Hammond,et al.  Targeting Hypoxic Cells through the DNA Damage Response , 2010, Clinical Cancer Research.

[16]  L. Holmberg,et al.  Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population‐based lymph node negative breast cancer cohort , 2010, International journal of cancer.

[17]  James B. Mitchell,et al.  Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs. , 2010, Free radical biology & medicine.

[18]  O. Gavet,et al.  Activation of cyclin B1–Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis , 2010, The Journal of cell biology.

[19]  K. Behrns,et al.  Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis , 2009, Cancer Chemotherapy and Pharmacology.

[20]  L. Xia,et al.  PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells. , 2009, Biochemical and biophysical research communications.

[21]  Fei Zou,et al.  Low concentration of GA activates a preconditioning response in HepG2 cells during oxidative stress—roles of Hsp90 and vimentin , 2009, Cell Stress and Chaperones.

[22]  J. Doroshow,et al.  Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly , 2007 .

[23]  C. Perez-stable,et al.  Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy , 2007, Molecular Cancer Therapeutics.

[24]  Viji M. Draviam,et al.  Hsp90 is required to localise cyclin B and Msps/ch-TOG to the mitotic spindle in Drosophila and humans , 2007, Journal of Cell Science.

[25]  G. Gores,et al.  Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. , 2005, Journal of hepatology.

[26]  K. Blackwell,et al.  Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? , 2004, The oncologist.

[27]  Hong Zhang,et al.  Hsp90 Activation and Cell Cycle Regulation , 2004, Cell cycle.

[28]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[29]  L. Montaño,et al.  Differential expression of a 70 kDa O-glycoprotein on T cells: a possible marker for naive and early activated murine T cells. , 2002, Cellular immunology.

[30]  R. Medema,et al.  Checking out the G(2)/M transition. , 2001, Biochimica et biophysica acta.

[31]  L. Porter,et al.  Abundance of cyclin B1 regulates γ-radiation–induced apoptosis , 2000 .

[32]  G. Giaccone,et al.  Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. , 2010, European journal of cancer.

[33]  A. Egloff,et al.  Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. , 2006, Cancer research.

[34]  L. Porter,et al.  Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis. , 2000, Blood.

[35]  L. Porter,et al.  Abundance of cyclin B 1 regulates g-radiation – induced apoptosis , 2000 .

[36]  T. Menovsky,et al.  Heat shock protein. , 1997, Journal of neurosurgery.